01942nam a2200397 i 4500001001300000003000600013005001700019007001400036008004100050040003000091042000800121043001200129074001600141086002200157088010100179110008500280245023900365264006000604300004900664336000800713337001600721338001900737500002500756500003600781500002500817504004100842533010600883776017500989776015801164050002101322610006001343650003301403650003301436650004201469655003301511on1045067223OCoLC20180815142001.0he bmb024bbca180719s2018    dcuab   bb   f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---  a1016-B (MF)0 aY 4.G 74/7:115-35  aSerial no. 115-35 (United States. Congress. House. Committee on Oversight and Government Reform)1 aUnited States.bCongress.bHouse.bCommittee on Oversight and Government Reform,10aOffice of National Drug Control Policy :breauthorization in the 115th Congress : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, July 26, 2017. 1aWashington :bU.S. Government Publishing Office,c2018.  aiii, 88 pages :billustrations, map ;c24 cm  btxt  bh2rdamedia  bhe2rdacarrier  a"Serial no. 115-35."  aShipping list no.: 2018-0099-M.  aCRDP Program record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2018]e1 microfiche : negative.08iPrint version:aUnited States. Congress. House. Committee on Oversight and Government Reform.tOffice of National Drug Control Policyw(DLC) 2017393116w(OCoLC)102431868508iOnline version:aUnited States. Congress. House. Committee on Oversight and Government Reform.tOffice of National Drug Control Policyw(OCoLC)1023431808 4aKF27b.O94 2017k10aUnited States.bOffice of National Drug Control Policy. 0aDrug controlzUnited States. 0aOpioid abusezUnited States. 0aDrug abusexTreatmentzUnited States. 7aLegislative hearings.2lcgft